MedTrace Logo

TT-702 in Patients With Advanced Solid Tumours.

NCT05272709 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 188

Last updated 2024-05-13

No results posted yet for this study

Summary

This clinical trial is evaluating the drug candidate TT-702 in patients with advanced solid tumours. The main aims of the trial are to determine the maximum dose of TT-702 that can be given safely to patients alone and in combination with other anti-cancer agents.

Conditions

Interventions

DRUG

TT-702

TT-702 will be administered orally, once daily, for up to 12 months.

DRUG

Darolutamide

Darolutamide will be administered orally, twice daily, for up to 12 months.

Sponsors & Collaborators

Principal Investigators

  • Johann de Bono, Prof · The Royal Marsden Hospital/ The Institute of Cancer Research

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-19
Primary Completion
2027-06-30
Completion
2027-06-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05272709 on ClinicalTrials.gov